<DOC>
	<DOCNO>NCT01203020</DOCNO>
	<brief_summary>This phase II study allogeneic hematopoietic progenitor cell transplantation ( HPCT ) follow reduce toxicity condition daily intravenous Busulfex fludarabine patient relapsed/chemotherapy refractory Hodgkin 's non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Once Daily Targeted Intravenous ( IV ) Busulfex Part Reduced-toxicity Conditioning Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation</brief_title>
	<detailed_description>This study hop learn give intravenous ( IV ) busulfan fludarabine ( condition regimen ) allogeneic hematopoietic progenitor cell transplantation ( HPC ) safe help patient Non—Hodgkin´s Lymphoma ( NHL ) Hodgkin´s Lymphoma ( HL ) . An HPC transplant take cell donor´s bone marrow , chemotherapy treatment condition regimen , infuses donor´s cell patient´s body . Busulfan strong drug suppresses immune system fludarabine chemotherapy ( cancer fight ) drug . These drug stop growth cancer cell break Deoxyribonucleic acid ( DNA ) genetic material necessary growth healthy cancer cell . The use IV busulfan fludarabine condition regimen prior HPC transplant investigational ( approve Food Drug Administration [ FDA ] ) . Busulfan give daily IV study , also approve FDA . Patients study go standard procedure disease like medical history , physical exam , blood test , Multi Gated Acquisition Scan ( MUGA ) scan echocardiogram , bone marrow aspirate biopsy , lung function test . Patients ask donate additional blood bone marrow study potential future research blood relate study . Because normal procedure HPC transplant patient study hospitalize 4 6 week longer make frequent trip clinic visit study doctor supervision least one year . Each patient also central venous catheter insert large vein heart . This used give drug take blood sample . Participation study last two year . The study expect enroll 32 patient open least two collaborate institution future . Upon initial Institutional Review Board ( IRB ) approval enrollment occur West Virginia University ( WVU ) . The IRB notify enrollment occurs institution .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients aged 1870 year age eligible . 2 . Eligible histology include : Bcell , Tcell NKcell NHL refractory frontline salvage therapy define failure achieve complete partial remission accord standard criterion . Diffuse large Bcell lymphoma relapse within 12 month finish rituximab contain first line chemotherapy regimen ( regardless response salvage chemotherapy ) evidence cmyc . Primary refractory NHL ( regardless response salvage chemotherapy ) . Hodgkin lymphoma chemorefractory least two prior therapy . Hodgkin NHL untreated relapse . Transformed NHL chronic lymphocytic leukemia undergo Richter 's transformation ( regardless response last chemotherapy ) . Patients chemosensitive relapse NHLs Hodgkin lymphoma , consider ineligible curative therapy autologous transplantation , ( ) inability collect stem cell , ( b ) prior autografting , ( c ) presence myelodysplasia ( ) histology consider curable autografting opinion treat physician eligible . 3 . All patient must least one suitable HLAmatched sibling volunteer unrelated donor available ( accord institutional guideline ) . HLA type perform least serological level HLAA , B , C allele level HLADRB1 . One antigen allele level mismatch permit donor recipient ; however donor/recipient pair must match HLADRB1 allele level . 4 . Patient must able provide inform consent . 5 . Left ventricular ejection fraction ≥ 40 % . No uncontrolled arrhythmia uncontrolled New York Heart Association class IIIIV heart failure . 6 . Bilirubin , aspartate aminotransferase ( AST ) , Alanine transaminase ( ALT ) ≤ 3 x normal ; absence hepatic cirrhosis . 7 . Adequate renal function define serum creatinine clearance ≥ 40 % normal calculate CockcroftGault equation . 8 . DLCO ( diffusion capacity ; correct hemoglobin ) force expiratory volume ( FEV1 ) ≥ 50 % predict . 9 . Karnofsky performance status ≥ 70 . 10 . A negative pregnancy test require woman child bear potential . Breast feeding permit . 1 . Patients eligible potentially curative therapy autologous transplantation . 2 . Patients lymphoblastic lymphoma . 3 . Patients positive human immunodeficiency virus ( HIV ) serology . 4 . Clinical evidence uncontrolled bacterial , viral fungal infection time transplant conditioning . 5 . Prior allogeneic transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hodgkin 's</keyword>
	<keyword>non-Hodgkin 's</keyword>
	<keyword>lymphoma</keyword>
	<keyword>allogeneic hematopoietic progenitor cell transplant</keyword>
	<keyword>HPCT</keyword>
	<keyword>busulfex</keyword>
	<keyword>fludarabine</keyword>
	<keyword>reduced-toxicity conditioning</keyword>
	<keyword>reduced-intensity conditioning</keyword>
</DOC>